GEn1E Lifesciences Inc

GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. They develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. GEn1E is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilitiescreating novel therapeutics at an unprecedented pace. Their AI platform has enabled them to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their...

Ards,inflammation,rare diseases,ai platform,clinical stage,immunomodulators,y combinator,inflammatory disease,next-generation,multi-target,novel drugs,techbio,machine learning,drug development,and drug discovery

Gen1e lifesciences inc operates in the Biotechnology research industry.

Gen1e lifesciences inc's revenue is 11m - 100m

Gen1e lifesciences inc has 11 - 50 employees.